Programmed Axon Death and its Roles in Human Disease
Dr.
University of Cambridge
Event Information
Host
McGill Neuro
Duration
70 minutes
Abstract
Axons degenerate before the neuronal soma in many neurodegenerative diseases. Programmed axon death (Wallerian degeneration) is a widely-occurring mechanism of axon loss that is well understood and preventable in animals. Its aberrant activation by mutation of the pro-survival gene Nmnat2 directly causes axonopathy in mice with severity ranging from mild polyneuropathy to perinatal lethality. Rare biallelic mutations in the homologous human gene cause related phenotypes in patients. NMNAT2 is a negative regulator of the prodegenerative NADase SARM1. Constitutive activation of SARM1 is cytotoxic and the human SARM1 locus is significantly associated with sporadic ALS. Another negative regulator, STMN2, has also been implicated in ALS, where it is commonly depleted downstream of TDP-43. In mice, programmed axon death can be robustly blocked by deletion of Sarm1, or by overexpression, axonal targeting and/or stabilization of various NMNAT isoforms. This alleviates models of many human disorders including some forms of peripheral neuropathy, motor neuron diseases, glaucoma, Parkinson’s disease and traumatic brain injury, and it confers lifelong rescue on the lethal Nmnat2 null phenotype and other conditions. Drug discovery programs now aim to achieve similar outcomes in human disease. In order to optimize the use of such drugs, we have characterized a range of human NMNAT2 and SARM1 functional variants that underlie a spectrum of axon vulnerability in the human population. Individuals at the vulnerable end of this spectrum are those most likely to benefit from drugs blocking programmed axon death, and disorders associated with these genotypes are promising indications in which to apply them.
Topics
Related Seminars
Deciphering the Dynamics of the Unconscious Brain under General Anesthesia
Stanford Neurosciences Seminar Series talk by Emery Brown (Massachusetts Institute of Technology, Neuroscience Statistics Research Lab) on deciphering the dynamics of the unconscious brain under…
Engineering human myelination in vitro: Mechanobiologically compatible platforms for CNS drug discovery
UCL Department of Neuroinflammation Seminar by Professor Emad Moeendarbary (Professor of Cell Mechanics and Mechanobiology, UCL Mechanical Engineering) on how biophysical factors such as substrate…
Colloquium on the Brain and Cognition with Christopher Harvey, PhD, Harvard University
Picower Institute Colloquium on the Brain and Cognition featuring Christopher Harvey, PhD, of Harvard University, held in Singleton Auditorium (46-3002) at MIT Building 46, 43 Vassar Street.
Related Job Opportunities
PhD Studentship: Mitochondrial Metabolism and Novel Therapeutic Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (Fixed Term)
A fully funded University of Cambridge PhD studentship, supported by Novo Nordisk, will investigate how mitochondrial metabolism changes during metabolic dysfunction-associated steatotic liver…
Research Associate (Fixed Term)
Kathy Niakan's laboratory at the Loke Centre for Trophoblast Research is recruiting a postdoctoral researcher to study early lineage specification in human pre- and early post-implantation embryos.…
Research Assistant/Associate (Fixed Term)
A fixed-term research position in the laboratories of Ole Paulsen and Jasper Poort will study neural mechanisms of visual learning in mice. The project combines patch-clamp electrophysiology…